As global markets navigate through economic uncertainties, the Hong Kong market has shown resilience, with the Hang Seng Index experiencing only a slight decline amid broader concerns about inflation and trade dynamics. In this context, growth companies with high insider ownership and strong revenue growth stand out as compelling opportunities for investors seeking stability and potential upside. When evaluating stocks in such an environment, it’s crucial to consider companies that not only demonstrate robust revenue growth but also have significant insider ownership. This alignment of interests between company insiders and shareholders can be a positive indicator of future performance.
Top 10 Growth Companies With High Insider Ownership In Hong Kong
|
Name |
Insider Ownership |
Earnings Growth |
|
Laopu Gold (SEHK:6181) |
36.4% |
34.7% |
|
Akeso (SEHK:9926) |
20.5% |
54.7% |
|
Fenbi (SEHK:2469) |
33.1% |
22.4% |
|
Zylox-Tonbridge Medical Technology (SEHK:2190) |
18.8% |
69.8% |
|
Pacific Textiles Holdings (SEHK:1382) |
11.2% |
37.7% |
|
Zhejiang Leapmotor Technology (SEHK:9863) |
14.7% |
78.9% |
|
DPC Dash (SEHK:1405) |
38.2% |
104.2% |
|
Beijing Airdoc Technology (SEHK:2251) |
29.1% |
93.4% |
|
Kindstar Globalgene Technology (SEHK:9960) |
16.5% |
88% |
|
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) |
13.9% |
109.2% |
Let’s uncover some gems from our specialized screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: BYD Company Limited, with a market cap of HK$773 billion, operates in the automobiles and batteries sector across China, Hong Kong, Macau, Taiwan, and internationally.
Operations: The company’s revenue segments include CN¥507.52 billion from Automobiles and Related Products and CN¥154.49 billion from Mobile Handset Components, Assembly Service, and Other Products.
Insider Ownership: 30.1%
Revenue Growth Forecast: 14.1% p.a.
BYD demonstrates strong growth potential with high insider ownership, reflected in its consistent production and sales increases. Recent unaudited results show a production volume of 2.32 million units year-to-date, up from 1.83 million units last year, and sales volume matching this growth. Earnings for the first half of 2024 reached CNY 13.63 billion, an increase from CNY 10.95 billion a year ago, highlighting robust financial performance amid strategic expansions and partnerships like the one with Uber Technologies.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Meituan operates as a technology retail company in the People’s Republic of China with a market cap of HK$777.88 billion.
Operations: The company’s revenue segments include New Initiatives at CN¥77.56 billion and Core Local Commerce at CN¥228.13 billion.
Insider Ownership: 11.6%
Revenue Growth Forecast: 12.9% p.a.
Meituan showcases significant growth potential with high insider ownership, evidenced by its robust earnings and active share buyback program. For the first half of 2024, Meituan reported net income of CNY 16.72 billion, doubling from CNY 8.05 billion a year ago. The company has repurchased over 139 million shares worth $2 billion under its buyback plan, reflecting strong confidence in its future prospects despite modest insider trading activity recently.
Simply Wall St Growth Rating: ★★★★★★
Overview: Akeso, Inc., a biopharmaceutical company with a market cap of HK$62.51 billion, researches, develops, manufactures, and commercializes antibody drugs.
Operations: The company generates CN¥1.87 billion from the research, development, production, and sale of biopharmaceutical products.
Insider Ownership: 20.5%
Revenue Growth Forecast: 33.1% p.a.
Akeso, a growth company with high insider ownership, has demonstrated promising clinical results for its ivonescimab treatments. Recent data from the European Society for Medical Oncology Conference highlighted the efficacy and safety of ivonescimab in treating triple-negative breast cancer and metastatic colorectal cancer. Despite reporting a net loss of CNY 238.59 million for H1 2024, Akeso’s innovative therapies and ongoing trials position it well for future growth in the biopharmaceutical sector.
Where To Now?
Ready For A Different Approach?
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include SEHK:1211 SEHK:3690 and SEHK:9926.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com